AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20546261 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 20546261 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal OGTT)
Number of subjects: 75
Study 18207532 — intervention group
Group type: COMPARATOR
Intervention: Preoperative only protocol (single dose of cefazolin IV)
Number of subjects: 233
Study 18207532 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative with extended postoperative antibiotic protocol (single dose of cefazolin IV followed by cefazolin IV every 8 hours for 3 days and oral cephalexin every 6 hours for 7 days)
Number of subjects: 233
Study 16398845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group (chest wall percussion and oropharyngeal suctioning)
Number of subjects: 177
Study 16398845 — intervention group
Group type: COMPARATOR
Intervention: Control group (suctioning without percussion unless indicated)
Number of subjects: 177
Study 16398845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group
Number of subjects: 177
Study 14728188 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based hypertutorials
Number of subjects: 2
Study 14728188 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'Book-on-the-Web' lessons
Number of subjects: 2
Study 10717780 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 135
Study 10717780 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 135
Study 10717780 — intervention group
Group type: COMPARATOR
Intervention: IUD (control)
Number of subjects: 135
Study 8877348 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for up to three months
Number of subjects: 15
Study 8877348 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 15
Study 1497158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg IM
Number of subjects: 18
Study 1497158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3862501 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Nashers programme (intervention group, n=35)
Number of subjects: 73
Study 3862501 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 73
Study 31672146 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg
Number of subjects: 20
Study 31672146 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 28498233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity monitor (WAM) in addition to supervised exercise programs (SEPs)
Number of subjects: 37
Study 28498233 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise programs (SEPs) only
Number of subjects: 37
Study 27028914 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg daily
Number of subjects: 527
Study 27028914 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily
Number of subjects: 527
Study 27028914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 25300286 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 55
Study 25300286 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 55
Study 25300286 — intervention group
Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 55
Study 20565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival processing
Number of subjects: 0
Study 20565216 — intervention group
Group type: COMPARATOR
Intervention: Moving scenario
Number of subjects: 0
Study 20565216 — intervention group
Group type: COMPARATOR
Intervention: Pleasantness scenario
Number of subjects: 0
Study 20565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized lists
Number of subjects: 0
Study 20565216 — intervention group
Group type: COMPARATOR
Intervention: DRM-like word lists
Number of subjects: 0
Study 16358844 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective surgery of the nasal obstruction
Number of subjects: 52
Study 16358844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 52
Study 12399209 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C plain polysaccharide vaccine (Mps)
Number of subjects: 195
Study 12399209 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C polysaccharide-diphtheria toxoid conjugate vaccine (Mcj)
Number of subjects: 195
Study 12399209 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated subjects)
Number of subjects: 195
Study 9120384 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct test (cued recall word-stem completion)
Number of subjects: 2
Study 9120384 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect test (repetition priming word-stem completion)
Number of subjects: 2
Study 9120384 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect assessments
Number of subjects: 2
Study 9120384 — intervention group
Group type: EXPERIMENTAL
Intervention: Final free recall test
Number of subjects: 2
Study 7838584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg)
Number of subjects: 8
Study 7838584 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.075 mg/kg)
Number of subjects: 8
Study 7838584 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 3202206 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.15 mg/kg)
Number of subjects: 30
Study 3202206 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 30
Study 3202206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11485845 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical delta-aminolaevulinic acid (ALA) applied under an occlusive dressing for 5 hours on 64 warts.
Number of subjects: 121
Study 11485845 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) applied to 57 warts.
Number of subjects: 121
Study 30015528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 30015528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30015528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (Japan substudy)
Number of subjects: 0
Study 30015528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Japan substudy)
Number of subjects: 0
Study 30015528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 0
Study 30333337 — intervention group
Group type: COMPARATOR
Intervention: Chloride liberal intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in 0.9% normal saline (Voluven), 0.9% normal saline, and Ringer's lactate
Number of subjects: 600
Study 30333337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride restricted intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in balanced colloid solution (Volulyte) and balanced salt crystalloid solution (PlasmaLyte A)
Number of subjects: 600
Study 27224953 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated training
Number of subjects: 48
Study 27224953 — intervention group
Group type: COMPARATOR
Intervention: Self-guided training
Number of subjects: 48
Study 27224953 — intervention group
Group type: EXPERIMENTAL
Intervention: All students
Number of subjects: 48
Study 24347384 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha with or without bevacizumab
Number of subjects: 1381
Study 22425091 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation
Number of subjects: 160
Study 22425091 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 160
Study 22425091 — intervention group
Group type: COMPARATOR
Intervention: Simple open prostatectomy
Number of subjects: 160
Study 20148732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-endoscopic drink of water containing Gascon and Pronase
Number of subjects: 112
Study 20148732 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic flushes of 20-ml aliquots of water containing Gascon, with or without Pronase
Number of subjects: 112
Study 20148732 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic flushes of 20-ml aliquots of water
Number of subjects: 112
Study 17587751 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg once daily
Number of subjects: 6
Study 15151912 — intervention group
Group type: EXPERIMENTAL
Intervention: Care home rehabilitation service
Number of subjects: 165
Study 15151912 — intervention group
Group type: COMPARATOR
Intervention: Usual health and social care (Control)
Number of subjects: 165
Study 11666127 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA (total triterpenic fraction of Centella asiatica) at a dose of 60 mg thrice daily for 12 months
Number of subjects: 60
Study 11666127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9699198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg/day
Number of subjects: 50
Study 9699198 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/day plus medroxyprogesterone acetate (MPA), 5 mg/day
Number of subjects: 50
Study 7989632 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup (30 mg/Kg) and diazepam solution (0.2 mg/Kg)
Number of subjects: 26
Study 7989632 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate syrup (30 mg/Kg) and diphenhydramine HCl (1.5 mg/Kg)
Number of subjects: 26
Study 2563924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 348
Study 2563924 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 348
Study 4537850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution as the sole intravenous fluid
Number of subjects: 0
Study 4537850 — intervention group
Group type: COMPARATOR
Intervention: Three different intravenous solutions to meet all fluid and electrolyte requirements
Number of subjects: 0
Study 31067371 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg vaginal suppositories twice daily)
Number of subjects: 4153
Study 31067371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching vaginal suppositories)
Number of subjects: 4153
Study 29110696 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hemostatic sponge
Number of subjects: 3
Study 29110696 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 3
Study 29110696 — intervention group
Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 3
Study 25919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 329
Study 25919527 — intervention group
Group type: COMPARATOR
Intervention: Referral
Number of subjects: 329
Study 25919527 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention
Number of subjects: 329
Study 23662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 19
Study 23662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (iPGI2) at 50 ng/kg/min
Number of subjects: 19
Study 23662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) in HFpEF patients
Number of subjects: 19
Study 23662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (iPGI2) in HFpEF patients
Number of subjects: 19
Study 23662176 — intervention group
Group type: COMPARATOR
Intervention: Inhaled epoprostenol (iPGI2)
Number of subjects: 19
Study 23662176 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 19
Study 23662176 — intervention group
Group type: COMPARATOR
Intervention: Combination of iNO and iPGI2
Number of subjects: 19
Study 21496284 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-taxane sequence (FE(100)C*3 followed by Docetaxel(100)*3)
Number of subjects: 4149
Study 21496284 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-containing chemotherapy (FE(100)C)
Number of subjects: 4149
Study 21496284 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological risk assessment using uPA/PAI-1
Number of subjects: 4149
Study 21496284 — intervention group
Group type: COMPARATOR
Intervention: Clinical-pathological algorithm
Number of subjects: 4149
Study 18273603 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 61
Study 18273603 — intervention group
Group type: COMPARATOR
Intervention: Protein beverage
Number of subjects: 61
Study 16649873 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR
Number of subjects: 362
Study 16649873 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 362
Study 15329203 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + Interferon (IFN)
Number of subjects: 62
Study 15329203 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 62
Study 11104313 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment alone
Number of subjects: 579
Study 11104313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Medication + Psychosocial treatment)
Number of subjects: 579
Study 11104313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 579
Study 11104313 — intervention group
Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 579
Study 9195505 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 0.5 mg subcutaneously twice per week
Number of subjects: 10
Study 9195505 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 1.0 mg subcutaneously twice per week
Number of subjects: 10
Study 9195505 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H)
Number of subjects: 10
Study 8338919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (B)
Number of subjects: 0
Study 8338919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide plus volume replacement (B + VR)
Number of subjects: 0
Study 8338919 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 100-mmol NaCl load (P + NaCl)
Number of subjects: 0
Study 8338919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide plus volume replacement plus 100-mmol NaCl load (B + VR + NaCl)
Number of subjects: 0
Study 2878275 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 19
Study 2878275 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 19
Study 2878275 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 19
Study 30371745 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed cumulative incidence regression models for dynamic treatment regimens (DTRs)
Number of subjects: 0
Study 30518052 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 supplementation (2g/day of DHA + EPA)
Number of subjects: 556
Study 30518052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 26709136 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and Sitagliptin (GS)
Number of subjects: 174
Study 26709136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 24401769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 93
Study 24401769 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 93
Study 22035368 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to chosen music for 30 minutes per week for 8 weeks)
Number of subjects: 50
Study 22035368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 50
Study 21106941 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin
Number of subjects: 0
Study 21106941 — intervention group
Group type: COMPARATOR
Intervention: losartan
Number of subjects: 0
Study 21106941 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 0
Study 18364361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Number of subjects: 145
Study 18364361 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 145
Study 15811208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ibandronate (2.5 mg)
Number of subjects: 2946
Study 15811208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946
Study 15811208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2946
Study 12432670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercised with music
Number of subjects: 30
Study 12432670 — intervention group
Group type: COMPARATOR
Intervention: Exercised without music
Number of subjects: 30
Study 10383833 — intervention group
Group type: EXPERIMENTAL
Intervention: MP+PGE1
Number of subjects: 275
Study 10383833 — intervention group
Group type: COMPARATOR
Intervention: CS+PGE1
Number of subjects: 275
Study 10383833 — intervention group
Group type: EXPERIMENTAL
Intervention: VER, TFP, PAP, MAN (MP)
Number of subjects: 275
Study 10383833 — intervention group
Group type: COMPARATOR
Intervention: VER, TFP, PAP (CS)
Number of subjects: 275
Study 7675622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive condition where children were informed that the armchair could move
Number of subjects: 40
Study 7675622 — intervention group
Group type: COMPARATOR
Intervention: Cognitive condition where children were informed that the armchair could not move
Number of subjects: 40
Study 2252195 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion of ketamine, midazolam, and alfentanil with inhalation of isoflurane in oxygen-enriched air
Number of subjects: 0
Study 6997513 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 37
Study 6997513 — intervention group
Group type: COMPARATOR
Intervention: Control (standard surgical therapy)
Number of subjects: 37
Study 31087060 — intervention group
Group type: EXPERIMENTAL
Intervention: ENFORCE prediction model
Number of subjects: 4036
Study 31087060 — intervention group
Group type: COMPARATOR
Intervention: ACCORD trial standard glycemic arm
Number of subjects: 4036
Study 28556775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 24
Study 28556775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study 26159634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 246
Study 26159634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 246
Study 26159634 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 246
Study 26159634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 246
Study 26159634 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 246
Study 23441738 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (heavy marcaine)
Number of subjects: 36
Study 23441738 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (propofol + nitric oxide)
Number of subjects: 36
Study 21421809 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 620
Study 21421809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 19835754 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Number of subjects: 76
Study 19835754 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement with socket grafting followed by provisionalization after 4 months
Number of subjects: 76
Study 17360317 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, self-efficacy, and optimism assessed prior to BMT
Number of subjects: 87
Study 17360317 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for age, gender, maximum grade of acute GVHD, and treatment arm
Number of subjects: 87
Study 15541449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS)
Number of subjects: 408
Study 15541449 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 408
Study 11719353 — intervention group
Group type: EXPERIMENTAL
Intervention: G-BM
Number of subjects: 57
Study 11719353 — intervention group
Group type: COMPARATOR
Intervention: G-PBSC
Number of subjects: 57
Study 9141149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 14
Study 9141149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7968073 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 7968073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 3311138 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for IGT
Number of subjects: 216
Study 3311138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 216
Study 2619026 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (Difflam) spray
Number of subjects: 0
Study 2619026 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 4623748 — intervention group
Group type: EXPERIMENTAL
Intervention: disodium cromoglycate (DSCG)
Number of subjects: 23
Study 4623748 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 29958055 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU vitamin D3
Number of subjects: 90
Study 29958055 — intervention group
Group type: COMPARATOR
Intervention: 1 ml normal saline (placebo)
Number of subjects: 90
Study 28061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Multireader, multicenter studies
Number of subjects: 201
Study 28061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial
Number of subjects: 201
Study 28061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical technical equivalence trial
Number of subjects: 201
Study 28061962 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 201
Study 25214516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 65